BFBoris Fishman

Boris Fishman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Boris Fishman has a total of 180 co-authors. Here are the top co-authors by number of shared publications:

  • Ehud Grossman

    Adelson School of Medicine, Ariel University, Ariel 4070000, Israel

    6 shared publications
  • Gilad Twig

    The Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Ramat Gan, Israel

    6 shared publications
  • Arnon Afek

    The Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Ramat Gan, Israel (T.T., A.A., G.T.).

    5 shared publications
  • Dorit Tzur

    Israel Defense Forces Medical Corps, Tel Hashomer, Ramat Gan (A.M.T., T.T., D.T., A.F.).

    4 shared publications
  • Elad Maor

    The Olga and Lev Leviev Heart Center at Sheba Medical Center, Ramat Gan, Israel; The Faculty of Medical and Health Sciences, Tel-Aviv University, Israel

    4 shared publications
  • Estela Derazne

    Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

    4 shared publications

Latest Publications

  • Open Access

    Sex-Specific Prognostic Significance of Interventricular Septal Thickness in Heart Failure

    by Alon Kaplan, Viana Copeland, Ranel Loutati, Boris Fishman, Yishay Wasserstrum, Assi Milwidsky, Tal Hasin, Rafael Kuperstein, Elad Maor, Michael Arad

    Background: Interventricular septal (IVS) thickness is routinely measured by echocardiography, yet its prognostic significance in heart failure (HF), and whether it differs by sex, remains uncertain. Methods: This retrospective study included patients with HF from the SHEBAHEART registry (2009-2025). IVS thickness was classified as normal (1.3 cm), using identical thresholds by sex. Associations with all-cause mortality were evaluated using Kaplan-Meier analysis and multivariable Cox models adjusted for age, body mass index, systolic blood pressure, comorbidities, and left ventricular ejection fraction, with formal testing for sex-by-IVS interaction. Results: Among 20,836 patients (median age, 74 years; 39% women), 41% had mild and 18% had severe IVS thickening. During a median follow-up of 4 years, 11,930 patients (57%) died; 4-year Kaplan-Meier cumulative mortality increased across IVS categories (35%, 39%, and 42%; P < 0.001). In primary complete-case analysis (n = 13,902), the sex-by-IVS interaction was significant (P = 0.030). Adjusted hazard ratios (95% confidence intervals) for mild and severe thickening were 1.16 (1.07-1.26) and 1.19 (1.08-1.32) in women, compared with 1.02 (0.96-1.09) and 1.07 (0.99-1.16) in men. The sex-by-IVS interaction remained significant in multiple-imputation and time-varying Cox analyses, but not with sex-specific IVS reference partitions. Conclusions: With common absolute IVS thresholds, increased septal thickness was more strongly associated with all-cause mortality in women than in men with HF. These findings support evaluation of IVS thickness as a potential component of sex-specific risk stratification in HF.

  • Open Access

    Irritable Bowel Syndrome and Allergic Diseases: A Nationwide Study of 1.5 Million Adolescents

    by Bar Cohen, Inbal Dym, Itay Nitzan, Nitzan Shakartzi-Kaminsky, Boris Fishman, Saleh Daher, Estela Derazne, Dorit Tzur, Ariel Furer, Gilad Twig, et al.

  • Adolescent Blood Pressure and Cardiovascular Disease Before Age 50 Years

    by Avishai M. Tsur, Tomer Talmy, Roy Hershenson, Boris Fishman, Estela Derazne, Dorit Tzur, Orit Pinhas-Hamiel, Asaf Vivante, Ehud Grossman, Ariel Furer, et al.

    BACKGROUND: Adolescent blood pressure guidelines rely on expert consensus because evidence on cardiovascular outcomes is limited. This study aimed to examine the link between adolescent blood pressure indices and early cardiovascular events. METHODS: We conducted a cohort study among 902 741 adolescents aged 16 to 19 years who were evaluated for mandatory service from 1979 to 2019, excluding those with preexisting cardiometabolic conditions. Individuals were followed until 50 or death or insurance loss or December 31, 2021, whichever occurred first. Exposures included baseline blood pressure and American Academy of Pediatrics categories: normal (<120/<80 mm Hg), elevated (120/<80–129/<80 mm Hg), stage 1 (130/80–139/89 mm Hg), stage 2 (≥140/90 mm Hg), and hypertension (clinical diagnosis). The primary outcome was incident cardiovascular events (ischemic heart disease or cerebrovascular disease). Hazard ratios were estimated using Cox models adjusted for demographic, socioeconomic, and clinical confounders. RESULTS: During over 18 million person-years of follow-up, 6305 cardiovascular disease events were recorded, yielding an incidence rate of 0.35 per 1000 person-years. Increased diastolic, systolic, and mean arterial blood pressure were significantly associated with increased risk. Compared with the Normal group, adjusted hazard ratios for cardiovascular disease were 1.14 (95% CI, 1.08–1.22) for stage 1, 1.31 (1.20–1.44) for stage 2, and 2.42 (1.87–3.12) for hypertension. Risk in the stage 1 category was particularly sensitive to diastolic blood pressure. CONCLUSIONS: Higher blood pressure indices during adolescence were strongly associated with an elevated risk of early cardiovascular disease, highlighting the potential need to refine current guidelines to better reflect cardiovascular risk.


  • Open Access

    The Safety Profile of Ticagrelor Among Older Adults (age ≥ 75 years): A Pharmacovigilance Analysis

    by Inbar Yacoby-Halevi, Boris Kruchin, Chen Gadot, Dmitri Guz, Assaf Rotmensh, Yonatan Shaleve, Hila Sharon, Noam Greenberg, Boris Fishman, Edward Itelman, et al.

    Introduction Ticagrelor is a widely used potent P2Y12 inhibitor in patients aged ≥75 years with acute coronary syndromes. Despite its widespread use, data on ticagrelor’s safety in older adults remain limited. Material & methods We performed a retrospective pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) from 2010 to 2024. Disproportionality analysis compared ticagrelor with clopidogrel, assessing predefined adverse events in adults (<75 years) and older adults (≥75 years). For each group, reporting odds ratios (RORs) with 95% confidence intervals (CI) were calculated, and differences between age groups were evaluated interaction analysis. Results A total of 6,476 ticagrelor-related adverse event reports were included: 4,795 (74%) adults and 1,681 (26%) older adults. In older adults, ticagrelor was not associated with increased reporting of dyspnea, intracranial hemorrhage, complete atrioventricular block, or gout. Acute kidney injury (AKI) was the only event reported more frequently in older adults (ROR 2.3 [95% CI 1.5–3.6] vs. 0.6 [95% CI 0.4–0.9]; p<0.001). Ticagrelor was associated with lower reporting of gastrointestinal bleeding, hematuria, hemoptysis, and anemia in both age subgroups. Bradycardia and syncope were reported more frequently among adults (p=0.002 and p<0.001, respectively). Conclusion Ticagrelor appears generally safe in older adults (≥75 years), with no excess reporting of major adverse events compared to younger adults, aside from a higher reporting of AKI. Keywords ACS, anti-platelets, Ticagrelor, elderly, adverse effect

  • Open Access

    Uric Acid Variability Is Associated with Poor Prognosis in Heart Failure

    by Viana Copeland, Shir Elimeleh, Assi Milwidsky, Noam Makmal, Ranel Loutati, Boris Fishman, Yishay Wasserstrum, Moti Zwilling, Elad Maor, Ehud Grossman

    Aims: Elevated uric acid (UA) levels correlate with worse heart failure (HF) outcomes, but past studies used single UA measurements. The effect of intra-individual UA fluctuations, beyond mean levels, is unclear. This study assesses the relationship between serum UA variability and adverse clinical outcomes in HF patients. Methods: We analyzed 18,115 HF patients from the SHEBAHEART registry (2009–2025) with at least three UA measurements within three years of diagnosis. UA variability was quantified as the mean deviation (MD) from each patient’s average UA level and divided into quartiles: Q1 (≤−0.69 mg/dL), Q2–Q3 (>−0.69 and p < 0.001). These associations remained after propensity score matching and across HF subgroups. Conclusions: UA variability is a robust, independent predictor of mortality and HF hospitalization. Serial UA monitoring may enhance risk stratification in HF management.


  • Open Access

    Frailty Modifies the Prognostic Effect of Age Among Older Adults With Acute Coronary Syndrome

    by Boris Fishman, Amitai Segev, Saar Ashri, Tsahi T. Lerman, Shani Sultani, Roy Beigel, Avishay Grupper, Fernando Chernomordik, Romana Herscovici, Adi Vinograd, et al.

    Background: An increasing number of older adults have been hospitalized in cardiac intensive care units. Their more complex medical profiles and frailty dictate treatment decisions and affect outcomes. There is no universally agreed‐upon age definition for an older adult, with common thresholds being 65 or 75 years. Our objective was to evaluate the predictive value of various age groups while accounting for frailty. Methods: In this observational cohort study, we analyzed data from a prospective registry of consecutive patients admitted to the cardiac intensive care unit at a tertiary hospital between January 2014 and March 2022 with a diagnosis of acute coronary syndrome. The primary outcome was the composite of 90‐day all‐cause death, shock, acute heart failure, acute kidney injury, stroke, mechanical ventilation, and ventricular arrhythmias. Frailty was dichotomized using the routinely measured Norton score for all inpatients; a ≤17 score was defined as frail. Results: The study included 4790 patients with acute coronary syndrome, divided into age groups: 2249 aged <65 years, 1294 aged 65 to 74 years, and 1247 aged ≥75 years, with a higher proportion of women in the older age groups. Due to the interaction between age and frailty, the cohort was divided and analyzed separately on the basis of frailty status. Among the nonfrail group (3915 [81.7%]), 16% reached the outcome. Adjusted odds ratios for the primary outcome in patients aged ≥75 years were 2.18 (95% CI, 1.69–2.81) and 1.46 (95% CI, 1.15–1.85) compared with those aged <65 years and 65 to 74 years, respectively. For patients aged 65 to 74 years compared with those <65 years, the odds ratio was 1.49 (95% CI, 1.16–1.91). In the frail group, where 60% reached the outcome, no significant association was found between age groups and outcomes. Conclusions: Our results suggest that frailty may be a surrogate for aging and is a stronger predictor than chronological age for adverse outcomes among patients with acute coronary syndrome in the cardiac intensive care unit.


  • Machine Learning Application for Bleeding Risk Prediction in Patients with Atrial Fibrillation Treated with Oral Anticoagulation

    by Tsahi T. Lerman, Shmuel Tiosano, Roy Beigel, Michal Cohen-Shelly, Ran Kornowski, Refael Munitz, David A. Nace, Shuja Hassan, Karen Scandrett, Daniel E. Forman, et al.

    Background: Atrial fibrillation (AF) is a prevalent cardiac arrhythmia associated with a significantly increased risk of systemic thromboembolism and stroke. Anticoagulation therapy, particularly with direct oral anticoagulants, has become the standard for stroke prevention but comes at the cost of an increased bleeding risk. With the introduction of effective alternatives to anticoagulation, such as percutaneous left atrial appendage occlusion, bleeding risk stratification has become essential to guide therapeutic decision-making. Conventional statistical methods have been used for bleeding risk stratification scores, such as HEMORR2HAGES, HAS-BLED, and ATRIA. However, these methods may inadequately address the multifactorial nature of bleeding risk in diverse patient populations, and their overall performance has been suboptimal. Summary and Key Messages: Recent advancements in machine learning (ML) offer promising opportunities to enhance bleeding risk prediction and optimize anticoagulation therapy. This review explores ML applications in AF patients receiving anticoagulation therapy, focusing on the development and validation of ML-based bleeding risk scores. These models have demonstrated improved predictive performance compared to traditional tools, leveraging complex datasets to identify nuanced patterns and interactions. Furthermore, ML-driven tools in warfarin management, including dose prediction, optimization of time in the therapeutic range, and the identification of drug-drug interactions, show significant potential to enhance patient safety and treatment efficacy.


  • The Safety Profile of Amiodarone Among Older Adults (Age ≥75 Years): A Pharmacovigilance Study from the FDA Data

    by Tsahi T. Lerman, Chen Gadot, Noam Greenberg, Boris Kruchin, Ori Rahat, Kirill Buturlin, Aharon Erez, Gustavo Goldenberg, Alon Barsheshet, Gregory Golovchiner, et al.


  • Adolescent Hypertension Is Associated With Stroke in Young Adulthood: A Nationwide Cohort of 1.9 Million Adolescents

    by Boris Fishman, Aya Bardugo, Yair Zloof, Cole D. Bendor, Carmit Libruder, Inbar Zucker, Miri Lutski, Amit Ram, Yael Hershkovitz, Omri Orr, et al.

    Background: Adult hypertension is a well-established risk factor for stroke in young adults (aged <55 years), and the effects are even more deleterious than at an older age. However, data are limited regarding the association between adolescent hypertension and the risk of stroke in young adulthood. Methods: A nationwide, retrospective cohort study of adolescents (aged 16–19 years) who were medically evaluated before compulsory military service in Israel during 1985 to 2013. For each candidate for service, hypertension was designated after constructed screening, and the diagnosis was confirmed through a comprehensive workup process. The primary outcome was ischemic and hemorrhagic stroke incidence as registered at the national stroke registry. Cox proportional-hazards models were used. We conducted sensitivity analyses by excluding people with a diabetes diagnosis at adolescence or a new diabetes diagnosis during the follow-up period, analysis of adolescents with overweight, and adolescents with baseline unimpaired health status. Results: The final sample included 1 900 384 adolescents (58% men; median age, 17.3 years). In total, 1474 (0.08%) incidences of stroke (1236 [84%] ischemic) were recorded, at a median age of 43 (interquartile range, 38–47) years. Of these, 18 (0.35%) occurred among the 5221 people with a history of adolescent hypertension. The latter population had a hazard ratio of 2.4 (95% CI, 1.5–3.9) for incident stroke after adjustment for body mass index and baseline sociodemographic factors. Further adjustment for diabetes status yielded a hazard ratio of 2.1 (1.3–3.5). We found similar results when the outcome was ischemic stroke with a hazard ratio of 2.0 (1.2–3.5). Sensitivity analyses for overall stroke, and ischemic stroke only, yielded consistent findings. Conclusions: Adolescent hypertension is associated with an increased risk of stroke, particularly ischemic stroke, in young adulthood.


  • Open Access

    The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study

    by Adam Goldman, Boris Fishman, Gilad Twig, Emanuel Raschi, Tali Cukierman-Yaffe, Yonatan Moshkovits, Alon Pomerantz, Ilan Ben-Zvi, Rachel Dankner, Elad Maor

    Background: As indications for sodium-glucose co-transporter-2 inhibitors (SGLT2i) are expanding, a growing number of older adults have become candidates for treatment. We studied the safety profile of SGLT2i among older adults.Methods: A retrospective, pharmacovigilance study of the FDA’s global database of safety reports. To assess reporting of pre-specified adverse events following SGLT2i among adults (< 75 years) and older adults (≥ 75), we performed a disproportionality analysis using the sex-adjusted reporting odds ratio (adj.ROR).Results: We identified safety reports of 129,795 patients who received non-insulin anti-diabetic drugs (NIAD), including 24,253 who were treated with SGLT2i (median age 60 [IQR: 51–68] years, 2,339 [9.6%] aged ≥ 75 years). Compared to other NIAD, SGLT2i were significantly associated with amputations (adj.ROR = 355.1 [95%CI: 258.8 − 487.3] vs adj.ROR = 250.2 [79.3 − 789.5]), Fournier gangrene (adj.ROR = 45.0 [34.5 − 58.8] vs adj.ROR = 88.0 [27.0 − 286.6]), diabetic ketoacidosis (adj.ROR = 32.3 [30.0 − 34.8] vs adj.ROR = 23.3 [19.2 − 28.3]), genitourinary infections (adj.ROR = 10.3 [9.4 − 11.2] vs adj.ROR = 8.6 [7.2 − 10.3]), nocturia (adj.ROR = 5.5 [3.7 − 8.2] vs adj.ROR = 6.7 [2.8 − 15.7]), dehydration (adj.ROR = 2.5 [2.3 − 2.8] vs adj.ROR = 2.6 [2.1 − 3.3]), and fractures (adj.ROR = 1.7 [1.4 − 2.1] vs adj.ROR = 1.5 [1.02 − 2.1]) in both adults and older adults, respectively. None of these safety signals was significantly greater in older adults (Pinteractionthreshold of 0.05). Acute kidney injury was associated with SGLT2i in adults (adj.ROR = 1.97 [1.85 − 2.09]) but not in older adults (adj.ROR = 0.71 [0.59 − 0.84]). Falls, hypotension, and syncope were not associated with SGLT2i among either adults or older adults.Conclusion: In this global post-marketing study, none of the adverse events was reported more frequently among older adults. Our findings provide reassurance regarding SGLT2i treatment in older adults, although careful monitoring is warranted.